World leader in stem cell expansion technologies and therapeutic products, Gamida Cell Ltd., join hands with University of Pittsburgh Cancer Institute (UPCI) to proceed the phase III trial of the ExCell research study.
The study is focused to assess the safety and efficacy of StemEx(R), an investigational product derived from stem cells.
StemEx is an alternative treatment to bone marrow transplants for hematological malignancies, including leukemia and lymphoma.
It is a graft of expanded stem progenitor cells taken from a single unit of umbilical cord blood and then transplanted in combination with non-expanded cells from the same unit.
Using umbilical cord blood stem cells instead of a traditional bone marrow transplant opens tremendous treatment possibilities for patients with diseases like leukemia and lymphoma.
Umbilical cord blood has two important advantages - it is a readily available source for stem cells and it has a lower matching requirement for patients. With StemEx(R), the cord blood unit is enriched with stem cells, which are critical for a successful transplantation.